PITTSBURGH — Mylan Inc. has introduced risperidone orally disintegrating tablets in strengths of 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg.
The company said Friday that the product, launched by its Mylan Pharmaceuticals Inc. subsidiary, is a generic version of Ortho-McNeil’s Risperdal M-Tab, a treatment for schizophrenia.
Last year, risperidone orally disintegrating tablets had U.S. sales of approximately $61 million, according to IMS Health data provided by Mylan.
An antipsychotic medication, risperidone is used to treat schizophrenia and symptoms of bipolar disorder, or manic depression.
